@miffyhelen I'm type 2 diabetic AND an inpatient pharmacist. Ever since I started taking #incretin drugs — first #Bydureon (#exenatide), then #Ozempic (#semaglutide), and most recently #Mounjaro (#tirzepatide) — it has transformed my experience of exercise. Before, I never understood how anyone could enjoy exercise. I suspect another diabetes drug of a different class, good old #metformin, is helping too. #Mounjaro, especially, has made a world of difference. If you're not diabetic, #tirzepatide is also available as a weight-loss drug under a different name (#Zepbound). And another #incretin drug, not approved yet, is on the horizon: #retatrutide. From everything I've read about it, it should be the best of all.

Nature Medicine asked 11 leading researchers for their top clinical trials to watch in 2023. The replies include #exenatide in #Parkinsonsdisease - the most prominent and promising Phase III #drugrepurposing trial in recent years -, autologous CRISPR–Cas9-modified CD34+ human stem and progenitor cells for #sicklecelldisease; and there should be more substantial data on #lecanemab for #Alzheimers disease: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798349/